First-in-human vaccine trial for deadly Nipah virus launched

JANUARY 11, 2024byUniversity of OxfordCredit: CC0 Public DomainThe University of Oxford has launched a new clinical trial to test a vaccine to protect people against deadly Nipah virus.This is t

Updated on: March 25,2024 4

First-in-human vaccine trial for deadly Nipah virus launched

JANUARY 11, 2024byUniversity of OxfordCredit: CC0 Public DomainThe University of Oxford has launched a new clinical trial to test a vaccine to protect people against deadly Nipah virus.This is t

Updated on:March 25,2024 4

Discovery identifies those likely to experience life-threatening dengue fever

by Monash UniversityStudy cohort characteristics. Individuals with a confirmed secondaryDENVinfection were recruited for the study at the onset of fever and followed up for progressio

Updated on: March 13,2024 16

Discovery identifies those likely to experience life-threatening dengue fever

by Monash UniversityStudy cohort characteristics. Individuals with a confirmed secondaryDENVinfection were recruited for the study at the onset of fever and followed up for progressio

Updated on:March 13,2024 16

New study highlights COVID-19's adaptive strategy for infection

byUniversity of Minnesota Medical SchoolCryo-EM analyses of residue 417 in regulating the conformation of recombinant SARS-CoV-2 spike ectodomain. Prototypic SARS-CoV-2 spike ectodomains contain

Updated on: January 26,2024 13

New study highlights COVID-19's adaptive strategy for infection

byUniversity of Minnesota Medical SchoolCryo-EM analyses of residue 417 in regulating the conformation of recombinant SARS-CoV-2 spike ectodomain. Prototypic SARS-CoV-2 spike ectodomains contain

Updated on:January 26,2024 13

Pain identified as dominant symptom in long COVID

byUniversity College LondonFifteen most prevalent long COVID symptoms. Credit:JRSM Open(2024). DOI: 10.1177/20542704241274292Pain may be the most prevalent and severe symptom reporte

Updated on: September 10,2024 0

Pain identified as dominant symptom in long COVID

byUniversity College LondonFifteen most prevalent long COVID symptoms. Credit:JRSM Open(2024). DOI: 10.1177/20542704241274292Pain may be the most prevalent and severe symptom reporte

Updated on:September 10,2024 0

Drug repurposing research offers new hope in the fight against RSV

by Jan Grabowski, Zentrum für Experimentelle und Klinische InfektionsforschungIdentification of drug repurposing candidates.AScreening and validation procedure.BHEp-2 cells wer

Updated on: May 21,2024 3

Drug repurposing research offers new hope in the fight against RSV

by Jan Grabowski, Zentrum für Experimentelle und Klinische InfektionsforschungIdentification of drug repurposing candidates.AScreening and validation procedure.BHEp-2 cells wer

Updated on:May 21,2024 3

Default testing for COVID-19 in K-12 schools more effective than voluntary testing

by Phil Ciciora,University of Illinois at Urbana-ChampaignGraphical Abstract. Credit:iScience(2023). DOI: 10.1016/j.isci.2023.108770A new paper co-written by a team of University of

Updated on: March 20,2024 20

Default testing for COVID-19 in K-12 schools more effective than voluntary testing

by Phil Ciciora,University of Illinois at Urbana-ChampaignGraphical Abstract. Credit:iScience(2023). DOI: 10.1016/j.isci.2023.108770A new paper co-written by a team of University of

Updated on:March 20,2024 20

How does SARS-CoV-2 evade our immune defenses?

by John Hewitt , Medical XpressColorized scanning electron micrograph of a cell (blue) heavily infected with SARS-CoV-2 virus particles (red), isolated from a patient sample. Image captured at the NIA

Updated on: April 22,2024 20

How does SARS-CoV-2 evade our immune defenses?

by John Hewitt , Medical XpressColorized scanning electron micrograph of a cell (blue) heavily infected with SARS-CoV-2 virus particles (red), isolated from a patient sample. Image captured at the NIA

Updated on:April 22,2024 20

COVID-19 vaccine responses to be studied in people with immune deficits

by NIH/National Institute of Allergy and Infectious DiseasesZebra-print ribbon, a symbol for awareness of primary immunodeficiencies and other rare diseases. Credit: NIAIDA study assessing how pe

Updated on: April 12,2024 19

COVID-19 vaccine responses to be studied in people with immune deficits

by NIH/National Institute of Allergy and Infectious DiseasesZebra-print ribbon, a symbol for awareness of primary immunodeficiencies and other rare diseases. Credit: NIAIDA study assessing how pe

Updated on:April 12,2024 19

Phase 3 clinical trial: Second-generation COVID vaccine generates high levels of neutralizing antibodies

by University of Washington School of MedicineVaccine GPB510 is a tiny ball of protein studded with 60 copies of the SARS-CoV-2 Spike protein receptor-binding domain (red). Credit: Ian Haydon / U

Updated on: April 02,2024 16

Phase 3 clinical trial: Second-generation COVID vaccine generates high levels of neutralizing antibodies

by University of Washington School of MedicineVaccine GPB510 is a tiny ball of protein studded with 60 copies of the SARS-CoV-2 Spike protein receptor-binding domain (red). Credit: Ian Haydon / U

Updated on:April 02,2024 16

How SARS-CoV-2 evades the immune system

by Hokkaido UniversityThe expression of the immune response gene NLRC5 (red purple) is suppressed in SARS-CoV-2 (green) infected cells (Photo: Koichi Kobayashi). Credit: Koichi KobayashiResearche

Updated on: April 22,2024 12

How SARS-CoV-2 evades the immune system

by Hokkaido UniversityThe expression of the immune response gene NLRC5 (red purple) is suppressed in SARS-CoV-2 (green) infected cells (Photo: Koichi Kobayashi). Credit: Koichi KobayashiResearche

Updated on:April 22,2024 12

Study explores characteristics associated with poor COVID-19 antibody response

by Melissa Rohman,Northwestern UniversityAnti-S1 IgG levels over time between first vaccine dose and serosurvey by socio-demographic and clinical correlates. Plot of predicted anti-S1 antibody l

Updated on: March 27,2024 0

Study explores characteristics associated with poor COVID-19 antibody response

by Melissa Rohman,Northwestern UniversityAnti-S1 IgG levels over time between first vaccine dose and serosurvey by socio-demographic and clinical correlates. Plot of predicted anti-S1 antibody l

Updated on:March 27,2024 0

Meningococcal disease on the rise in the US

by Deb Balzer,Mayo ClinicNeisseria meningitidisbacteria, responsible for causing meningococcal meningitis. Credit: CDCA rise in invasive serogroup Y meningococcal disease has prompted the

Updated on: April 30,2024 0

Meningococcal disease on the rise in the US

by Deb Balzer,Mayo ClinicNeisseria meningitidisbacteria, responsible for causing meningococcal meningitis. Credit: CDCA rise in invasive serogroup Y meningococcal disease has prompted the

Updated on:April 30,2024 0